WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTC: ACTC) announced today that it has received a total of $400,000 in additional funding through the receipt of the final payment from CHA Biotech Co, Ltd., a leading Korean-based biotechnology company focused on the development of stem cell technologies, in connection with its recently formed international joint venture with Advanced Cell; and research grants from the National Institutes of Health. Proceeds from these transactions as well as other transactions in advanced discussions will be used to support the Company’s retinal pigment epithelium cells (RPE) program. The Company anticipates filing an IND with the FDA during the second half of this year.
